ArticleCureus2019
Evaluation of Serum Glial Cell Line-derived Neurotrophic Factor in Bangladeshi Major Depressive Disorder Patients.
Article in Cureus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Evaluation of inflammatory cytokines in drug-naïve major depressive disorder: A systematic review and meta-analysis.International journal of immunopathology and pharmacologyPooled it
- Trial
- Increased serum EGF but not SDF-1 levels are associated with the pathophysiology and development of generalized anxiety disorder.Scientific reports · 2024Article
- Evaluation of serum interleukin-12 and interleukin-4 as potential biomarkers for the diagnosis of major depressive disorder.Scientific reports · 2024Article
- Serum levels of interleukin-33 and mesencephalic astrocyte derived neurotrophic factors in patients with major depressive disorder: a cross-sectional comparative design.BMC psychiatry · 2024Article
- Evaluation of serum MIP-1β and MCP-2 levels in major depressive disorder: A case-control study.PloS one · 2024Article
- Altered IL-3 and lipocalin-2 levels are associated with the pathophysiology of major depressive disorder: a case-control study.BMC psychiatry · 2023Article
- Evaluation of serum interleukin-1 receptor antagonist levels in major depressive disorder: A case-control study.Health science reports · 2023Article
- Higher serum nerve growth factor levels are associated with major depressive disorder pathophysiology: a case-control study.The Journal of international medical research · 2023Article
- Higher serum interleukin-12 levels are associated with the pathophysiology of major depressive disorder: A case-control study results.Health science reports · 2023Article
- Serum Cortisol, Nesfatin-1, and IL-1β: Potential Diagnostic Biomarkers in Elderly Patients with Treatment-Resistant Depression.Clinical interventions in aging · 2022Article
- Article
- Associations of serum cystatin C with depressive symptoms and suicidal ideation in major depressive disorder.BMC psychiatry · 2021Article
- Elevated Serum IL-2 Levels are Associated With Major Depressive Disorder: A Case-Control Study.Clinical pathology (Thousand Oaks, Ventura County, Calif.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Major depressive disorder (MDD) is a global health burden in the 21
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.